Prognostic utility of ctDNA before and after trimodality therapy (TMT) for muscle invasive bladder cancer.
Lists
Only you see this
Abstract
4578 Background: Outside of standard patient and tumor characteristics, biomarkers predicting outcomes after TMT for non-metastatic muscle-invasive bladder cancer (MIBC) are lacking. Tumor-informed circulating tumor DNA (ctDNA) has identified MIBC patients at risk of relapse following radical cystectomy. This study assessed the clinical utility of a ctDNA assay in predicting disease progression following TMT. Methods: We retrospectively identified patients (pts) with MIBC (cT2-T4, cN0-N2, cM1) who had TMT between 2019 and 2024 and ctDNA assessment with a personalized, tumor-informed assay (Signatera, Natera, Inc) before and/or after TMT. Standard clinical variables extracted include TNM stage, risk factors at TURBT (carcinoma in situ (CIS) and hydronephrosis) age of diagnosis, primary radiotherapy (RT) dose, chemotherapy regimen/duration, and if elective nodal irradiation (ENI) was received. We analyzed the impact of pre-TMT or post-TMT ctDNA (MTM/mL), as well as changes in ctDNA, on disease-free survival (DFS) using the Kaplan-Meier method. We assessed the impact of ENI on DFS in cN0 pts with positive ctDNA at baseline. Predictors of recurrence were assessed with univariate Cox proportional hazard models. Results: Among 34 pts, median age was 69 (interquartile range (IQR) 62-79), majority were male (91%), had cT2 (73.5%), were cN0 (85%), had no CIS (76%) or hydronephrosis (94%). The median dose of RT was 64 Gy. Ten (29%) patients had detectable ctDNA prior to TMT. Median follow-up was 13.2 months from last RT dose of TMT. Pts with detectable ctDNA after TMT had inferior DFS compared to pts with persistently undetectable (pre/post-TMT) or pts with ctDNA clearance (median survival of 5 months vs 15 and 19 months, respectively, log-rank p = 0.056). Table 1 shows results for predictors of DFS after TMT. Pts with detectable ctDNA post-TMT (n = 4) all developed distant metastatic recurrence. Local recurrences did not present with a detectable ctDNA following TMT. Pts with measurable ctDNA at baseline demonstrated potentially prolonged DFS after ENI (n = 4) compared to the non-ENI cohort (n = 6), but did not meet statistical significance (7.6 months vs not reached, p = 0.2). Conclusions: Persistently detectable ctDNA following TMT correlates with disease-free survival. Larger cohorts are needed to assess role of ENI in pts with detectable ctDNA prior to TMT. These results are hypothesis-generating and should be validated prospectively. Predictors of DFS after TMT. HR (95% CI) P-value Histologic type (Reference (Ref) group: Pure urothelial) Urothelial with minor variant 0.76 (0.21-2.84) 0.69 CIS on TURBT (Ref group: No CIS) CIS 0.61 (0.16-2.28) 0.46 Pre-TMT Hydronephrosis (Ref group: No Hydronephrosis) Hydronephrosis 3.63 (0.77-17.19) 0.1 Response of ctDNA status to TMT (Ref group: Detectable to Detectable) Detectable to Undetectable 0.12 (0.02-1.00) 0.05 Undetectable to Undetectable 0.26 (0.04-1.75) 0.17
BibTeX
@article{raizenne2025prognostic,
author = {Brendan L. Raizenne and Vadim S. Koshkin and Suzanne M. Dufault and Terence W. Friedlander and Julian C. Hong and Carissa Chu and Nataliya Mar and Jonathan Chou and Martín Ma and Sima P. Porten and Steven N. Seyedin},
title = {{Prognostic utility of ctDNA before and after trimodality therapy (TMT) for muscle invasive bladder cancer.}},
journal = {Journal of Clinical Oncology},
year = {2025},
doi = {10.1200/jco.2025.43.16\_suppl.4578},
}Loading related content...